Hsf1 as a marker in tumor prognosis and treatment
AssigneesWhitehead Institute for Bio-Medical Research, The Brigham and Women's Hospital, Inc.
InventorsSandro Santagata, Susan Lindquist, Luke J. Whitesell, Tan A. Ince
Life of this patent
Estimating the term…
Abstract
In some aspects, the invention relates to Heat Shock Protein-1 (HSF1) gene and HSF1 gene products. In some aspects, the invention provides methods of tumor diagnosis, prognosis, treatment-specific prediction, or treatment selection, the methods comprising assessing the level of HSF1 expression or HSF1 activation in a sample obtained from the tumor. In some aspects, the invention relates to the discovery that increased HSF1 expression and increased HSF1 activation correlate with poor outcome in cancer, e.g., breast cancer.
Claims66
A method of diagnosing cancer in a subject comprising the steps of:
- determining the level of Heat Shock Factor-1 (HSF1) expression or the level of HSF1 activation in a sample obtained from the subject, wherein increased HSF1 expression or increased HSF1 activation in the sample is indicative that the subject has cancer.
A method of identifying cancer comprising the steps of:
- (a) providing a biological sample;
- and (b) determining the level of HSF1 expression or the level of HSF1 activation in the sample, wherein increased HSF1 expression or increased HSF1 activation in the sample is indicative of cancer.
A method of assessing a tumor with respect to aggressiveness, the method comprising:
- determining the level of HSF1 expression or HSF1 activation in a sample obtained from the tumor, wherein an increased level of HSF1 expression or activation is correlated with increased aggressiveness, thereby classifying the tumor with respect to aggressiveness.
A method of classifying a tumor according to predicted outcome comprising steps of:
- determining the level of HSF1 expression or HSF1 activation in a sample obtained from the tumor, wherein an increased level of HSF1 expression or activation is correlated with poor outcome, thereby classifying the tumor with respect to predicted outcome.
A method of predicting cancer outcome in a subject, the method comprising:
- determining the level of HSF1 gene expression or the level of HSF1 activation in a tumor sample, wherein an increased level of HSF1 expression or activation is correlated with poor outcome, thereby providing a prediction of cancer outcome.
A method for providing prognostic information relating to a tumor, the method comprising:
- determining the level of HSF1 expression or HSF1 activation in a tumor sample from a subject in need of tumor prognosis, wherein if the level of HSF1 expression or HSF1 activation is increased, the subject is considered to have a poor prognosis.
A method for providing treatment-specific predictive information relating to a tumor, the method comprising:
- determining the level of HSF1 expression or HSF1 activation in a tumor sample from a subject in need of tumor prognosis, wherein the level of HSF1 expression or HSF1 activation correlates with tumor sensitivity or resistance to a treatment, thereby providing treatment-specific predictive information.
A method of determining whether a subject with a tumor is a suitable candidate for treatment with a proteostasis modulator, comprising assessing the level of HSF 1 expression or HSF1 activation in a tumor sample obtained from the subject, wherein an increased level of HSF1 expression or an increased level of HSF1 activation in the sample is indicative that the subject is a suitable candidate for treatment with a proteostasis modulator.
A method of predicting the likelihood that a tumor will be sensitive to a protein homeostasis modulator, the method comprising:
- (a) determining the level of HSF1 gene expression or the level of HSF1 activation in a sample obtained from the tumor;
- and (b) comparing the level of HSF1 gene expression or HSF1 activation with a control level of HSF1 gene expression or HSF1 activation, wherein if the level determined in (a) is greater than the control level, the tumor has an increased likelihood of being sensitive to the protein homeostasis modulator.
A method for tumor diagnosis, prognosis, treatment-specific prediction, or treatment selection comprising:
- (a) providing a sample obtained from a subject in need of diagnosis, prognosis, treatment-specific prediction, or treatment selection for a tumor;
- (b) determining the level of HSF1 expression or HSF1 activation in the sample;
- (c) scoring the sample based on the level of HSF1 expression or HSF1 activation, wherein the score provides diagnostic, prognostic, treatment-specific predictive, or treatment selection information.
Dependencies are inferred from the claim text.